ARTICLE | Company News
Lanthio, Tarix in pulmonary deal
February 22, 2012 1:38 AM UTC
Lanthio Pharma B.V. (Groningen, the Netherlands) granted Tarix Pharmaceuticals Ltd. (Brookline, Mass.) exclusive, worldwide rights to its lanthionine-Ang(1-7) peptide. According to Lanthio, the preclinical product targets the MAS receptor and is being developed for acute lung injury and related indications. Lanthio is eligible for milestones and royalties and Tarix will be responsible for funding further development. Details were not disclosed. ...